The use of endocrine therapy in the prevention of estrogen receptor (ER)-positive DCIS progression was first reported in 1999 by the National Surgical Adjuvant Breast and Bowel Project (NSABP B-24). This evidence concerns the gene ESR1 and ductal breast carcinoma in situ.